

## Mélanie Caron

---


**De:** Kate Lee [REDACTED]  
**Envoyé:** 1 mars 2021 11:10  
**À:** Mélanie Caron; Susan Cowan  
**Cc:** [REDACTED]  
**Objet:** RE: Follow up meeting re: Biosimilar switch

**Avertissement automatisé :** Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et les pièces jointes si vous ne reconnaissez pas l'expéditeur.

Hello Ms. Caron,  
Sue is away this week but, on behalf of Crohn's and Colitis Canada, thank you for your response.

We look forward to Mme Perreault's email.

Sincerely,  
Kate



**Kate Lee, PhD, MBA**  
Vice President, Research and Patient Programs  
**Crohn's and Colitis Canada**  
600 - 60 St. Clair Ave. E., Toronto ON M4T 1N5  
T: 416-920-5035 x 214  
Get Gutsy: [Learn](#) | [Volunteer](#) | [Donate](#)



---

**From:** Mélanie Caron [REDACTED]

**Sent:** February 27, 2021 3:36 PM

**To:** Susan Cowan [REDACTED]  
[REDACTED]

**Subject:** RE: Follow up meeting re: Biosimilar switch

Bonjour,

It will be great to reconnect and discuss about the situation in Québec.  
I'm away for spring break with until march 8<sup>th</sup>.

Mme Perreault will get back to you and propose a date for the meeting.

Thanks

Mélanie Caron, Pharm D, ICD.D

Conseillère spéciale en pharmacie et télésanté

Direction générale des affaires universitaires, médicales, infirmières et pharmaceutiques

Ministère de la Santé et des Services sociaux

[2021, avenue Union,](#)

[Montréal \(Québec\) H3A 2S9](#)

Tél. : [514-709-4644](#)

---

De : Susan Cowan [REDACTED]

Envoyé : 26 février 2021 11:53

À : Mélanie Caron [REDACTED]; Martine Perreault [REDACTED]  
[REDACTED]

Objet : Follow up meeting re: Biosimilar switch

**Avertissement automatisé :** Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et les pièces jointes si vous ne reconnaissez pas l'expéditeur.

Dear Ms. Caron,

I am Sue Cowan, the interim CEO of Crohn's and Colitis Canada. I hope this email finds you well.

I am following up on a meeting held with Crohn's and Colitis Canada's former President & CEO – Mina Mawani – and yourself on Quebec's consideration of implementing a biologic to biosimilar switch policy.

We understand that the Quebec government has been contacting gastroenterologists and other patient organizations to re-initiate consultations leading up to the government's switch policy.

As Mina mentioned, Crohn's and Colitis Canada is the only national health charity focused on research and supporting Crohn's disease and ulcerative colitis patients through education, awareness and advocacy. In preparation for our follow up meeting, we held a roundtable of gastroenterologists and patients and have conducted surveys.

To support Quebec's decision on the switch policy, we are reaching out to request a meeting with you and/or Ms. Perreault at your earliest convenience to share this information.

We hope to work with you to support cost savings along with ensuring the health of Quebec constituents living with Crohn's disease and ulcerative colitis. We are looking forward to hearing from you.

Sincerely,

Sue



**Susan Cowan**

Chief Executive Officer

**Crohn's and Colitis Canada**

600 - 60 St. Clair Ave. E., Toronto ON M4T 1N5

T: 416-920-5035 x 222 | C: 416-629-0080

Get Gutsy: [Learn](#) | [Volunteer](#) | [Donate](#)

*Please exercise caution in opening links or attachments from outside senders.*